Author

A. Lev

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

D. Dicker· 2 shared L. Zhou· 2 shared N. Ahsan· 2 shared S. Zhang· 2 shared W. El-Deiry· 2 shared X. Tian· 2 shared A. Arbiv· 1 shared A. Hendel· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Dicker

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Multiplex HDR for Disease and Correction Modeling of SCID by CRISPR Genome Editing in Human HSPCs

O. Iancu, D. Allen, O. Knop, Y. Zehavi, D. Breier, A. Arbiv, A. Lev, Y. N. Lee, K. Beider, A. Nagler, R. Somech, A. Hendel

This paper models SCID and tests gene correction in human HSPCs using CRISPR-Cas9 and multiplexed HDR, showing successful T-cell development from corrected cells.

bioRxiv · Oct 7, 2022Bioengineering

A subset of CB002 xanthine analogues bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53

L. Hernandez Borrero, D. T. Dicker, J. Santiago, J. Sanders, X. Tian, N. Ahsan, A. Lev, L. Zhou, W. S. El-Deiry

The paper identifies CB002 analogues that restore p53 signaling and target an S-phase checkpoint in p53-mutated tumors, inducing apoptosis and reducing proliferation without harming normal cells.

eLife · Jul 29, 2021Peer-reviewedCancer Biology

HIF1α inhibition by dual targeting of CDK4/6 and HSP90 reduces cancer cell viability including Rb-deficient cells

S. Zhao, L. Zhou, D. Dicker, A. Lev, S. Zhang, W. El-Deiry

This study shows that combining CDK4/6 and HSP90 inhibitors reduces HIF1 expression and cancer cell viability, including in Rb-deficient cells.

bioRxiv · Oct 20, 2020 · PreprintCancer Biology

P53-independent restoration of p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9

X. Tian, N. Ahsan, A. Lulla, A. Lev, P. Abbosh, D. Dicker, S. Zhang, W. El-Deiry

PG3-Oc restores p53 pathway signaling in mutant-p53 tumors through ATF4 modulation by ERK1/2 and CDK9, inducing p53 effector genes for cell death and tumor suppression.

bioRxiv · Oct 20, 2020Cancer Biology